High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone.

ABSTRACT: Blood levels of the soluble receptor for advanced glycation end-products (sRAGE) are acutely elevated during the host inflammatory response to infection and predict mortality in COVID-19. However, the prognostic performance of this biomarker in the context of treatments to reduce inflammation is unclear. In this study we investigated the association between sRAGE and mortality in dexamethasone-treated COVID-19 patients. We studied 89 SARS-CoV-2 positive subjects and 22 controls attending the emergency department of a University Teaching Hospital during the second wave of COVID-19 and measured sRAGE at admission. In positive individuals sRAGE increased with disease severity and correlated with the National Early Warning Score 2 (Pearson's r = 0.56, p < 0.001). Fourteen out of 72 patients tr

SUBMITTER: Butcher L 

PROVIDER: S-EPMC9637291 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature